Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta.
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta;
J Vis Exp. 2022 Mar 9(181). doi: 10.3791/63452.
Deficiency of the mitochondrial respiratory chain complexes that carry out oxidative phosphorylation (OXPHOS) is the biochemical marker of human mitochondrial disorders. From a genetic point of view, the OXPHOS represents a unique example because it results from the complementation of two distinct genetic systems: nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, OXPHOS defects can be due to mutations affecting nuclear and mitochondrial encoded genes. The groundbreaking work by King and Attardi, published in 1989, showed that human cell lines depleted of mtDNA (named rho) could be repopulated by exogenous mitochondria to obtain the so-called "transmitochondrial cybrids." Thanks to these cybrids containing mitochondria derived from patients with mitochondrial disorders (MDs) and nuclei from rho cells, it is possible to verify whether a defect is mtDNA- or nDNA-related. These cybrids are also a powerful tool to validate the pathogenicity of a mutation and study its impact at a biochemical level. This paper presents a detailed protocol describing cybrid generation, selection, and characterization.
线粒体呼吸链复合物缺陷是人类线粒体疾病的生化标志物,这些复合物执行氧化磷酸化(OXPHOS)。从遗传角度来看,OXPHOS 是一个独特的例子,因为它是由两个不同的遗传系统——核 DNA(nDNA)和线粒体 DNA(mtDNA)的互补组成的。因此,OXPHOS 缺陷可能是由于影响核编码和线粒体编码基因的突变引起的。1989 年 King 和 Attardi 的开创性工作表明,耗尽 mtDNA(称为 rho)的人细胞系可以通过外源性线粒体重新填充,以获得所谓的“传递线粒体杂种细胞”。由于这些含有源自线粒体疾病(MD)患者的线粒体和 rho 细胞核的杂种细胞,可以验证缺陷是与 mtDNA 还是 nDNA 相关。这些杂种细胞也是验证突变致病性和研究其在生化水平上影响的有力工具。本文介绍了详细的杂种细胞生成、选择和鉴定方案。